Lv41
760 积分 2024-03-05 加入
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
5小时前
待确认
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
9小时前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
8天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
10天前
已完结
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
10天前
已完结
BiTE: Teaching antibodies to engage T-cells for cancer therapy
14天前
已关闭
Influence of various medium environment to in vitro human T cell culture
1个月前
已完结
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy
2个月前
已完结
Biology and regulation of IL-2: from molecular mechanisms to human therapy
2个月前
已完结
An engineered viral protein activates STAT5 to prevent T cell suppression
4个月前
已完结
皖公网安备34019202002308
